OVERVIEW

Applying Precision Medicine for Patient-Centered, Quality Care for Acute Myeloid Leukemia (AML) is organized by Prime Education, LLC.

Release Date: February 14, 2020
Expire Date: February 14, 2021

Accreditation:
Physician Credit Designation Statement:
PRIME® designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Interprofessional Teams
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.
Nurse Practitioner Accreditation Statement:
This activity is approved for 1.0 contact hour of continuing education (which includes 0.25 hour of pharmacology) by the American Association of Nurse Practitioners.
Physician Assistant Accreditation Statement:
PRIME® has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit.
Nurse Accreditation Statement
PRIME® designates this activity for 1.0 contact hour.
Case Manager Accreditation Statement
The Commission for Case Manager Certification designates this educational activity for 1.0 contact hour for certified case managers.

Overview:
With the rapid expansion of targeted treatment options for difficult-to-treat patients with Acute Myeloid Leukemia (AML), hematology/oncology teams must integrate patient-, disease-, and treatment-related factors to ensure personalized treatment decision-making.

Listen in as our expert faculty discuss:
• Integrating molecular testing into treatment decision-making
• Aligning care with evidence-based guidelines
• Facilitating shared decision-making strategies to provide AML patients with quality care